Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyra Therapeutics, Inc. (Nasdaq: LYRA) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. Lyra identifies itself in these filings as a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), with its common stock listed on The Nasdaq Capital Market under the symbol LYRA.
Through Lyra’s Forms 10-K and 10-Q, readers can review detailed financial statements, including collaboration revenue, research and development expenses related to the ENLIGHTEN Phase 3 clinical program for LYR-210, general and administrative costs, restructuring charges, and cash and cash equivalents balances. These periodic reports also describe the company’s status as a clinical-stage entity with no approved products and discuss risks such as ongoing losses, funding needs, and dependence on clinical trial outcomes.
Current reports on Form 8-K document material events that are important for understanding LYRA’s situation. Examples include notices from The Nasdaq Stock Market regarding compliance with listing requirements, such as minimum bid price and stockholders’ equity thresholds; details of a registered direct offering and concurrent private placement of warrants; and changes in board and executive roles. Other 8-K filings reference the posting of corporate presentations that discuss LYR-210 and the ENLIGHTEN clinical program.
For those interested in clinical and strategic developments, Lyra’s filings and attached exhibits often cross-reference press releases that summarize ENLIGHTEN 2 Phase 3 results, pooled analyses in patients with nasal polyps, and regulatory interactions with the U.S. Food and Drug Administration. More recent corporate updates, including the decision by Lyra’s Board of Directors to suspend further development of LYR-210 and cease product development operations, are reflected in company disclosures and provide important context for interpreting financial and risk disclosures.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools can help readers quickly identify key sections in lengthy reports, such as risk factors, management’s discussion and analysis, restructuring notes, and disclosures related to Nasdaq listing status, financing agreements, and strategic alternatives under consideration.
Lyra Therapeutics (NASDAQ:LYRA) filed an 8-K on June 26, 2025 disclosing a registered direct offering and concurrent private placement.
The company sold 273,012 common shares, 150,360 pre-funded warrants (exercise $0.001) and 846,744 private warrants (exercise $11.56) at a combined price of $11.81, generating about $4.3 million in net proceeds.
- H.C. Wainwright earns a 7 % placement fee plus 6.5 % on any future warrant cash exercise.
- Private warrants are immediately exercisable, expire 24 months after the resale registration statement is declared effective and include Black-Scholes cash-out rights upon a fundamental transaction.
- Beneficial-ownership caps: 9.99 % for pre-funded warrants, 4.99 % (optionally 9.99 %) for private warrants.
- Proceeds will fund working capital and further clinical, manufacturing and pre-commercial activities for LYR-210.
No additional material events were reported.
Lyra Therapeutics has announced a combined offering of 273,012 shares of common stock and pre-funded warrants to purchase 150,360 shares. The offering includes:
- Common stock priced at $11.81 per share with two accompanying private warrants
- Pre-funded warrants at $11.809 per underlying share with $0.001 exercise price
- Private warrants to purchase up to 846,744 shares at $11.56 exercise price
The total offering is expected to raise approximately $5 million before expenses, with $350,001 in placement agent fees. H.C. Wainwright & Co. is acting as exclusive placement agent. The company recently announced positive Phase 3 ENLIGHTEN 2 trial results for LYR-210 in chronic rhinosinusitis patients, meeting its primary endpoint with statistically significant improvement in cardinal symptoms at week 24.
The offering is subject to Form S-3 limitations, with aggregate market value of common stock held by non-affiliates at $29.2 million. Post-offering shares outstanding will be approximately 1.74 million, assuming full exercise of pre-funded warrants.
Lyra Therapeutics, Inc. (ticker: LYRA) filed a Rule 424(b)(5) prospectus supplement dated June 26, 2025 that updates its April 1, 2024 at-the-market (ATM) offering documents.
The company has been selling common stock through Cantor Fitzgerald & Co. under an Amended and Restated Controlled Equity Offering Sales Agreement. To date, 7,059,228 shares have been issued, generating aggregate gross proceeds of $24,835,145.28.
This supplement’s sole purpose is to suspend the ATM Program and terminate the continuous offering effective June 26, 2025. No further shares will be sold under the existing prospectus until the company files a new supplement. Importantly, the underlying Sales Agreement with Cantor remains in full force, preserving the framework for potential future issuances.
The U.S. Securities and Exchange Commission has neither approved nor disapproved the securities described. All other terms and disclosures in the April 1, 2024 Base Prospectus and prior supplement remain unchanged unless expressly superseded herein.
Lyra Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)). The company received written confirmation from Nasdaq on June 13, 2025 that its common stock maintained a bid price above $1.00 for 12 consecutive business days from May 28, 2025 to June 12, 2025.
Key details:
- Trading Symbol: LYRA on Nasdaq Capital Market
- Stock Type: Common Stock ($0.001 par value per share)
- Company Status: Emerging growth company
- Compliance Issue: Now resolved and closed
This development removes a significant regulatory concern for the company and ensures continued listing on the Nasdaq Capital Market. The filing was signed by CFO Jason Cavalier on June 23, 2025.